Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of MBX-2982 Administered Daily for 4 Weeks as Monotherapy in Patients With Type 2 Diabetes

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
CymaBay Therapeutics, Inc.
ClinicalTrials.gov Identifier:
NCT01035879
First received: December 17, 2009
Last updated: March 30, 2015
Last verified: March 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: August 2010
  Primary Completion Date: August 2010 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Received: February 16, 2015